Search

Your search keyword '"Zukunft, Sven"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Zukunft, Sven" Remove constraint Author: "Zukunft, Sven" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
38 results on '"Zukunft, Sven"'

Search Results

1. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i

2. Role of the soluble epoxide hydrolase in keratinocyte proliferation and sensitivity of skin to inflammatory stimuli

3. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

4. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

5. Role of the soluble epoxide hydrolase in the hair follicle stem cell homeostasis and hair growth

7. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

8. ADPGK‐AS1 long noncoding RNA switches macrophage metabolic and phenotypic state to promote lung cancer growth

10. Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

12. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

13. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study

14. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens

16. Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence

17. P528: CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?

18. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)

19. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

20. Supplementary Table from Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation

21. Supplementary Figure from Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation

22. Data from Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation

23. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

25. Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

26. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

27. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

28. A novel role for cystathionine γ lyase in the control of p53: impact on endothelial senescence and metabolic reprograming

30. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

31. Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD

32. Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation

33. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

34. Impact of KMT2A-PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

35. Tandem Duplications of the UBTFgene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

36. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

37. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

38. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Catalog

Books, media, physical & digital resources